• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 91

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph...

MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH...

Algernon Pharmaceuticals Announces Closing of Rights Offering

Optimi Health Announces CAD$1.2 Million GMP Psilocybin Supply Agreement for Clinical...

Psychedelics Weekly – Psychedelics and Sports, The Risks of Over-Regulation, and...

COMPASS Pathways plc to announce first quarter 2023 financial results on...

The Top 5 Psychedelic Clinical Trials of 2022

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

Psychedelics, The Brain, and the Future of Mental Health

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine)...

1...909192...301Page 91 of 301

EDITOR PICKS

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots...

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©